Mstone's affiliate, Curyx Partners, L.L.C. is a privately-held holding company engaged in an innovative drug development. The company operates subsidiary companies that are involved in drug development by harboring druggable and/or commercially applicable intellectual properties in the fields of CNS disorders, respiratory diseases, gastrointestinal (GI) disorders, liver disorders, lysosomal storage disorders (LSD), lipid disorders, dermatology, and aesthetics originated from academic and research institutions in the US, EU, and Asia. Our strategy focuses on creating unique and risk-adjusted value from investing in selected drug candidates that qualify for expedited FDA approval including orphan drugs, specialty drugs, repurposed drugs, and novel therapeutics targeting diseases with a high unmet medical need. Another of our affiliate, Forest Hills Partners Hong Kong Limited, also known as Forest Hills Lab, focuses on cosmeceutical products such as HA fillers, meso serum and related cosmetic products as well as innovative therapeutic drugs for treating Parkinson's disease and Alzheimer's disease.
Mstone Partnerscontact us